_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
